Clinical Trials Browser

Phase 2 × Salivary Gland Neoplasms × Sorafenib × Clear all

NCT00939627 2026-03-10

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

Phase 2 Completed

55 enrolled 10 charts

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT01703455 2023-10-19

Activity of Sorafenib in Salivary Gland Cancer

Phase 2 Completed

Salivary Gland Neoplasms